Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan

Objective The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data...

Full description

Saved in:
Bibliographic Details
Published in:Modern rheumatology 2012-09, Vol.22 (5), p.712-719
Main Authors: Suematsu, Rie, Ohta, Akihide, Matsuura, Emi, Takahashi, Hiroki, Fujii, Takao, Horiuchi, Takahiko, Minota, Seiji, Ishigatsubo, Yoshiaki, Ota, Toshiyuki, Takei, Shuji, Soejima, Sachiko, Inoue, Hisako, Koarada, Syuichi, Tada, Yoshifumi, Nagasawa, Kohei
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Antirheumatic Agents - therapeutic use
Arthritis
C-Reactive Protein - analysis
Child
Drug Substitution
Drug therapy
Effectiveness
Etanercept
Female
Ferritins - blood
Humans
Immunoglobulin G - therapeutic use
Infliximab
Kaplan-Meier Estimate
Male
Medicine
Medicine & Public Health
Middle Aged
Monoclonal antibodies
Original Article
Orthopedics
Patients
Receptors, Tumor Necrosis Factor - therapeutic use
Retrospective Studies
Rheumatology
Still's Disease, Adult-Onset - blood
Still's Disease, Adult-Onset - drug therapy
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The efficacy of biologics in treating adult Still’s disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.
ISSN:1439-7595
1439-7609
DOI:10.1007/s10165-011-0569-6